Table 2.
Baseline Characteristics of Patients Who Discontinued Bisphosphonates, Stratified by Those Who Restarted Any Osteoporosis (OP) Therapy and Those Who Did Not
| Alendronate (20,455) |
Risedronate (2388) |
Zoledronic acid (3348) |
|||||
|---|---|---|---|---|---|---|---|
| Did not restart OP therapy |
Restarted OP therapy |
Did not restart OP therapy |
Restarted OP therapy |
Did not restart OP therapy |
Restarted OP therapy |
||
| No. (%) | 18,270 (89.3) | 2185 (10.7) | 2069 (86.6) | 319 (13.4) | 2702 (78.6) | 736 (21.4) | |
| Age (years) at index date | Mean (SD) | 79.2 (7.1) | 78.0 (6.3) | 79.5 (7.2) | 77.7 (6.5) | 79.5 (6.8) | 77.7 (6.2) |
| 65–69 (%) | 1501 (8.2) | 184 (8.4) | 168 (8.1) | 35 (11.0) | 212 (7.8) | 70 (9.5) | |
| 70–74 (%) | 4509 (24.7) | 633 (29.0) | 522 (25.2) | 90 (28.2) | 583 (21.6) | 205 (27.9) | |
| 75–79 (%) | 4229 (23.1) | 529 (24.2) | 423 (20.4) | 76 (23.8) | 641 (23.7) | 199 (27.0) | |
| 80–84 (%) | 3913 (21.4) | 507 (23.2) | 434 (21.0) | 70 (21.9) | 621 (23.0) | 164 (22.3) | |
| 85+ (%) | 4118 (22.5) | 332 (15.2) | 522 (25.2) | 48 (15.0) | 645 (23.9) | 98 (13.3) | |
| Race (%) | White | 15,975 (87.4) | 1897 (86.8) | 1815 (87.7) | 268 (84.0) | 2587 (95.7) | 708 (96.2) |
| Geographic region on index date (%) | Midwest | 5833 (31.9) | 699 (32.0) | 437 (21.1) | 60 (18.8) | 935 (34.6) | 245 (33.3) |
| Northeast | 3397 (18.6) | 365 (16.7) | 538 (26.0) | 79 (24.8) | 419 (15.5) | 88 (12.0) | |
| South | 5881 (32.2) | 722 (33.0) | 731 (35.3) | 124 (38.9) | 1101 (40.7) | 327 (44.4) | |
| West | 3159 (17.3) | 399 (18.3) | 363 (17.5) | 56 (17.6) | 247 (9.1) | 76 (10.3) | |
| Ever DXA (%) | Yes | 15,685 (85.9) | 1950 (89.2) | 1757 (84.9) | 297 (93.1) | 2547 (94.3) | 704 (95.7) |
| Ever CQ major fragility fracture (%) | Yes | 2967 (16.2) | 365 (16.7) | 355 (17.2) | 49 (15.4) | 665 (24.6) | 189 (25.7) |
| Ever CQ hip fracture (%) | Yes | 846 (4.6) | 89 (4.1) | 104 (5.0) | 9 (2.8) | 147 (5.4) | 35 (4.8) |
| Ever CQ vertebral fracture (%) | Yes | 1331 (7.3) | 175 (8.0) | 144 (7.0) | 26 (8.2) | 388 (14.4) | 113 (15.4) |
| Ever steroid (%) | Yes | 11,393 (62.4) | 1394 (63.8) | 1300 (62.8) | 203 (63.6) | 2223 (82.3) | 609 (82.7) |
| Charlson score category (%) | 0 | 9028 (49.4) | 1149 (52.6) | 1030 (49.8) | 155 (48.6) | 1219 (45.1) | 373 (50.7) |
| 1–2 | 4749 (26.0) | 567 (25.9) | 512 (24.7) | 98 (30.7) | 789 (29.2) | 205 (27.9) | |
| 3+ | 4493 (24.6) | 469 (21.5) | 527 (25.5) | 66 (20.7) | 694 (25.7) | 158 (21.5) | |
DXA = dual-energy X-ray absorptiometry; CQ = case qualifying.